Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NFE2L2 (nuclear factor, erythroid 2-like 2)

Written2014-09Stavroula D Manolakou, Panos G Ziros, Gerasimos P Sykiotis
Service of Endocrinology, Diabetology, Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland (SDM, PGZ, GPS); Faculty of Biology, Medicine, University of Lausanne, 1011 Lausanne, Switzerland (GPS)

(Note : for Links provided by Atlas : click)


Alias (NCBI)NRF2
HGNC (Hugo) NFE2L2
HGNC Alias symbNRF2
HGNC Alias nameNF-E2-related factor 2
HGNC Previous namenuclear factor (erythroid-derived 2)-like 2
 nuclear factor, erythroid 2-like 2
LocusID (NCBI) 4780
Atlas_Id 44284
Location 2q31.2  [Link to chromosome band 2q31]
Location_base_pair Starts at 177230309 and ends at 177264727 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping NFE2L2.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ACTR2 (2p14) / NFE2L2 (2q31.2)N4BP1 (16q12.1) / NFE2L2 (2q31.2)NDUFS6 (5p15.33) / NFE2L2 (2q31.2)
NFE2L2 (2q31.2) / CSAD (12q13.13)NFE2L2 (2q31.2) / HNRNPD (4q21.22)NFE2L2 (2q31.2) / KIF5B (10p11.22)
NFE2L2 (2q31.2) / NACA (12q13.3)NFE2L2 (2q31.2) / NFE2L2 (2q31.2)NFE2L2 (2q31.2) / PDE11A (2q31.2)
NFE2L2 (2q31.2) / RFTN2 (2q33.1)NFE2L2 (2q31.2) / ZC3H13 (13q14.13)PAX8 (2q13) / NFE2L2 (2q31.2)
PAX8 (2q14.1) / NFE2L2 (2q31.2)RPL18 (19q13.33) / NFE2L2 (2q31.2)SPG21 (15q22.31) / NFE2L2 (2q31.2)
Note The transcription factor Nrf2, encoded by the NFE2L2 gene, is the mediator of a cellular antioxidant response. Nrf2 belongs to the cap'n'collar (cnc) family of transcription factors.


  NFE2L2 gene - transcript variants. NFE2L2 gene located on chromosome 2. Multiple transcript variants (TV) encoding different isoforms have been found for this gene. The transcript variants referenced more often in the literature are NM_006164.4 (TV 1), NM_001145412.2 (TV 2) and NM_001145413.2 (TV 3).
Description The NFE2L2 gene is approximately 34.8 kb in size. The mouse homologue of the NFE2L2 gene is a self- and hetero-inducible gene; its promoter region contains two ARE/EpRE (antioxidant or electrophile response element) sequences at -492 bp and -754 bp, through which it is induced by Nrf2. In addition, its regulatory region contains three XRE (xenobiotic response element) sequences at -712 bp, +755 bp and +850 bp. ARE and XRE sequences are implicated in the inducible upregulation of the genes transcription. A kB2 region for NF-κB binding has been detected at +270 bp; proinflammatory stimuli can induce human NFE2L2 transcription via this element. On the other hand, five CpG sequences in the promoter region of NFE2L2 allow hypermethylation and repression of gene expression (Kwak et al., 2002; Hayes and Dinkova-Kostova, 2014).
Transcription NM_006164.4 (TV 1) comprises 5 coding exons and is approximately 2.8 kb in size; this transcript encodes the longest protein isoform. NM_001145412.2 (TV 2) and NM_001145413.2 (TV 3) comprise 4 coding exons each and are approximately 2.7 kb and 2.4 kb in size, respectively.

miRNA3128 is a non-coding RNA that is the transcript product of a region in the first intron of NFE2L2 (chr. 2: 177255945-177256010, complement). It is not known whether it has a role in the regulation of NFE2L2 expression. Micro RNAs species reported to suppress NFE2L2 expression include miR-27a, miR-28, miR-34a, miR-93, miR-142-5p, miR-144, and miR-153 (Filipowicz et al., 2008; Cheng et al., 2013; Hayes and Dinkova-Kostova, 2014).


Note Name: Nuclear factor erythroid 2-related factor 2. Short: NF-E2-related factor 2, NFE2-related factor 2.
Alternatives names: Nuclear factor, erythroid derived 2, like 2, NF-E2 p45-related Factor-2.
Nrf2, the nuclear factor erythroid 2 (NF-E2)-related transcription factor 2, was first described in 1994 by Moi et al. by screening for factors that could bind to a NFE2-binding DNA sequence. The human Nrf2 protein NP_006155.2 (encoded by TV 1) is 67.8 kDa in weight and consists of 605 amino acids; NP_001138884.1 (encoded by TV2) is 66.1 kDa in weight and consists of 589 amino acids; and NP_001138885.1 (encoded by TV3) is 65.4 kDa in size and consists of 582 amino acids.
Nrf2 has been characterized as a modulator protein and is the core of the Nrf2 antioxidant system/pathway. Other main components of the pathway are Keap1, the negative regulator of Nrf2, and small Maf proteins which serve as cofactors for Nrf2 binding to regulatory DNA sequences of ARE-regulated genes (Moi et al., 1994; Li and Kong, 2009).
  Structural and functional domains of Nrf2. A. Structural features of the human Nrf2 protein that dictate its activity. The interaction with Keap1 is mediated by the Neh2 (Nrf2 extended homology 2) domain of Nrf2. B. Nuclear localisation signals (NLS) and nuclear export signals (NES) have been detected in the Nrf2 sequence. The NESTA motif is the only one shown to be directly redox-sensitive. C. Specific cysteine residues have been characterised as reactive, meaning that they are sensitive to oxidation. Oxidative stress also activates intracellular kinases such as PKC and Fyn which in turn phosphorylate Nrf2 (on Ser40 and Tyr568, respectively) contributing to Nrf2 activation (Jain et al., 2005; Zhang, 2006).
Description Nrf2 binds to ARE sites of antioxidant genes as a heterodimer. Specifically, Nrf2 heterodimerizes with small Maf proteins (which are themselves devoid of transcription activating domains) to induce the transcription of ARE-regulated genes. Other binding partners include members of the AP-1 transcription factor family like Jun and Fos. In contrast, homodimers or heterodimers of the different small Maf proteins, and heterodimers of Bach proteins with small Maf proteins on AREs, have been characterised as negative regulators of Nrf2 signalling pathway that compete with Nrf2 for binding to AREs. The co-factor CBP/p300 is indispensable for transcription activation by Nrf2 and localizes to ARE-binding sites in association with Nrf2-small Maf heterodimers (Dhakshinamoorthy et al., 2005; Ishikawa et al., 2005; Li et al., 2008; Hirotsu et al., 2012).
  Crystal structures of the Nrf2-binding domain of Keap1 (Keap1 DC/Kelch domain) in complex with peptides derived from the Keap1-binding domain of Nrf2 (the DLG motif of the mouse Neh2 domain or the ETGE motif of the human Neh2 domain).
Expression Nrf2 is considered to be ubiquitously expressed, as it has been shown to be expressed in various cell types (including lung, liver, kidney, stomach, small intestine, neurons, astrocytes, etc) and it has been considered a multi-organ protector that enhances the cellular resistance to potential harmful insults that occur during cells' normal activities and during environmental exposures. Morevoer, Nrf2 has been found to be overexpressed in various human cancers (Yoo et al., 2012; Lee and Surh, 2005).
  A. Keap1 binds Nrf2 and inhibits its transcriptional activity. The depicted "hinge-and-latch" model proposes a 2:1 Keap1:Nrf2 molecular stoichiometry. B. At the basal cellular state (low oxidative burden), Nrf2 undergoes Keap1-Cul3-mediated poly-ubiquitination and proteasomal degradation.
Localisation Nrf2 can be detected both in the cytoplasm and in the nucleus; the Keap1-mediated degradation of Nrf2 occurs in the cytoplasm. In addition, one of the proposed models for the Keap1-Nrf2 interaction suggests that a Keap1 dimer can bind one Nrf2 molecule and one PGAM5 molecule. PGAM5 possesses a N-terminal membrane targeting signal, through which the Nrf2-Keap1-PGAM complex is tethered to the cytosolic surface of the outer mitochondrial membrane. As a result, Nrf2 can be also localised in the perimitochondrial region (Sykiotis and Bohmann, 2010).
  Two mechanistic models for the Nrf2-Keap1 interaction. Adapted from Sykiotis and Bohmann, 2010.
Function The Nrf2/Keap1 pathway is a major mediator of cytoprotective responses to oxidative and electrophilic stress. Nrf2 responds to oxidative stress by inducing the transcriptional upregulation of a broad range of cytoprotective genes whose promoters contain Antioxidant Response Element (ARE) sequences. Specifically, Nrf2 translocates to the nucleus, heterodimerizes with small Maf proteins and binds to ARE sequences to induce gene transcription. When redox balance is restored, Nrf2 activity is repressed via export from the nucleus back into the cytoplasm and degradation via a Cullin - RING ligase 3 - Keap1 complex (CRLkeap1 complex), and by other mechanisms (Zhang, 2006).

Oxidative stress and the antioxidant transcriptional response mediated by Nrf2
Cells and tissues are constantly exposed to various oxidative substances and electrophilic chemicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), derived from both endogenous and exogenous sources. To adapt to the oxidative environment, cells have developed elaborate and highly efficient antioxidant machineries. When pro-oxidant and electrophilic challenges overwhelm the cell's antioxidant and detoxification proteins, cells experience oxidative stress. Oxidative stress conditions can cause damage to cellular structures, including lipids, proteins, and nucleic acids. Among other injuries, this can lead to mutations and epigenetic perturbations by damaging DNA and proteins that modify chromatin. Thus, oxidative stress can be a causative or exacerbating factor in a range of diseases, including, for example, respiratory and metabolic disorders, neurodegenerative diseases, and cancer. 
In order to maintain homeostasis in the face of oxidative insults, cells possess signalling pathways that can sense oxidative stress and launch adaptive responses. Multiple ways of managing the intracellular oxidative load have been identified over the last two decades; among them, it has been recognized that gene transcription can be regulated by redox reactions. Prominent among the redox-sensitive pathways of gene activation is the Nrf2 system. The core of this pathway comprises the transcription factor Nrf2 and its negative regulator Keap1. In addition, small Maf proteins serve as dimerization partners of Nrf2 to facilitate its binding to DNA on special sequences termed antioxidant response elements (AREs) or electrophile response elements (EpREs) in the regulatory regions of the many Nrf2-regulated genes, including the genes encoding glutamate cysteine ligase catalytic subunit (GCLC), heme oxygenase-1 (HO-1), NADP(H) quinone oxidoreductase-1 (NQO1), microsomal glutathione-S-transferases such as MGST1 and MGST2, and multi-drug resistance-associated proteins such as ATP-binding cassette, subfamily C (CFTR/MRP), member 1 (ABCC1) (Magesh et al., 2012; Hayes and Dinkova-Kostova, 2014).

Activity and regulation of Nrf2
The Nrf2 pathway responds to oxidative stress by inducing the transcriptional upregulation of a broad range of cytoprotective genes. The Nrf2 system responds to both endogenous reactive molecules, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), and to exogenous substances. The sensing mechanisms comprise oxidation or alkylation of critical Keap1 cysteine residues (including Cys151, Cys273 and Cys288), and phosphorylation of Nrf2 on amino acids Ser40 and Tyr568 (Zhang and Hannink, 2003; Yamamoto et al., 2008; Magesh et al., 2012).
When redox homeostasis is restored, Nrf2 activity is repressed via export from the nucleus back into the cytoplasm and degradation via a Cullin-RING ligase 3 - Keap1 complex (CRLkeap1 complex). Nrf2 can also trigger a feedback loop of increased expression of ARE-dependent genes including Keap1 and Cul3, which then promote Nrf2 degradation and thus participate in resetting Nrf2 activity at its basal level (Rachakonda et al., 2008; Eggler et al., 2009; Baird and Dinkova-Kostova, 2011).

Activation of Nrf2 pathway
A. Transcriptional induction of the NFE2L2 gene
A1. Nrf2 autoregulation
It has been shown that the promoter of the mouse orthologue of the NFE2L2 gene includes two antioxidant response element-like sequences (ARE-L1 and ARE-L2), which are located at -492 bp and -754 bp from the transcription start site, respectively. It has been proposed that under stress conditions newly translated Nrf2 protein escapes Keap1-mediated degradation and binds to the ARE-L1 and ARE-L2 sequences to induce NFE2L2 gene transcription in a feed-forward manner (Shin et al., 2007; Hayes and Dinkova-Kostova, 2014).
A2. NFE2L2 transcription induced by the oncoproteins K-Ras and B-Raf
It has been demonstrated that oncogene-directed increased expression of the NFE2L2 gene can be an alternative mechanism of Nrf2 activation. K-Ras and B-Raf, which operate in the , have been shown to increase NFE2L2 transcription via activation of Jun or/and Myc. It has been proposed that via this mechanism oncogenic signaling may modulate redox homeostasis during tumirogenesis (DeNicola et al., 2011).
A3. Cross-talk of Nrf2 with the NF-κB and AhR signaling pathways
In general, the effects of the intracellular events induced by Nrf2 activation lead to NF-κB suppression, and vice versa; thus, overall, Nrf2 signaling antagonises NF-κB signaling. Nevertheless, in acute myeloid leukemia it has been reported that Nrf2 is upregulated by NF-κB-mediated transactivation of the NFE2L2 gene by direct binding of NF-κB to the NFE2L2 promoter (Rushworth et al., 2012).
The AhR/ARNT complex (aryl hydrocarbon receptor / AhR nuclear translocator) regulates gene transcription in response to xenobiotics, such as polycyclic aromatic hydrocarbons, via binding to xenobiotic response elements (XREs). Three XRE-like elements have been identified in the mouse Nfe2l2 promoter; via these elements, the AhR/XRE pathway can control Nrf2/ARE signaling (Miao et al., 2005).
A4. BRCA1 / ARNT-mediated induction of NFE2L2 gene transcription
The transcription factor BRCA1 (breast cancer 1, early onset) has been reported to increase the transcription of the NFE2L2 gene. As BRCA1 has the ability to interact with ARNT, it is possible that BRCA1 induces Nrf2 expression in an ARNT-dependent manner (Kang et al., 2006).
B. Post-translational activation of Nrf2
B1. The "hinge and latch" and "quaternary" models
At basal conditions (meaning the absence of oxidative stress) the NFE2L2 gene is constantly transcribed and Nrf2 protein is constantly synthesized, but Nrf2 protein abundance and activity are maintained at low levels due to the negative regulation of Nrf2 by Keap1 through the CRLkeap1 complex.
The "hinge and latch" model has been proposed as a mechanistic model that accounts for the interaction between Nrf2 and Keap1 and provides as structural basis for the Keap1-dependent polyubiquitination and degradation of Nrf2. This model posits an interaction of one Nrf2 molecule with a Keap1 homodimer, in which the high affinity binding of the ETGE motif of the Neh2 domain of Nrf2 functions as a "hinge" to fix Nrf2 to one of two Keap1 molecules, whereas the low affinity binding of the DLG motif of the Neh2 domain of Nrf2 functions as a "latch" to lock down the Neh2 domain to the other Keap1 molecule of the homodimer. The fixation of the Neh2 domain between the two Keap1 molecules thus facilitates its ubiquitination and the subsequent degradation of Nrf2 by the 26S proteasome. A competing structural model is the "quaternary complex" model, which proposes that a Keap1 dimer binds two molecules of substrate through high-affinity interactions with ETGE motifs. Specifically, a Keap1 dimer can bind two Nrf2 molecules, or one Nrf2 molecule and one PGAM5 molecule. PGAM5 possesses an N-terminal membrane targeting signal through which the Nrf2-Keap1-PGAM complex is tethered to the cytosolic surface of the outer mitochondrial membrane (Tong et al., 2006; Sykiotis and Bohmann, 2010; Kansanen et al., 2012), potentially to allow Nrf2 to be activated in response to mitochondrial leakage of ROS.
Under conditions of oxidative stress, it is believed that the oxidative modification of certain cysteine residues of Keap1 leads to conformational changes of the Keap1 dimer. In the "hinge and latch" model, this results in dissociation of the DLG motif from Keap1, wuch that Nrf2 cannot be properly presented for ubiquitination by the CRLkeap1 complex and thus escapes proteosomal degradation. The stabilized Nrf2 accumulates in the nucleus where it heterodimerizes with small Maf proteins and binds to AREs, leading to transcription of ARE-dependent cytoprotective genes (reviewed in Sykiotis and Bohmann, 2010; Hayes and Dinkova-Kostova, 2014).
B2. Phosphorylation of Nrf2 by PKC
Several protein kinases, including protein kinase C (PKC), have been implicated in the upstream regulation of Nrf2 pathway. Specifically, phosphorylation of Nrf2 by PKC induces nuclear translocation of this transcription factor and activation of the ARE in response to oxidative stress. Furthermore, it has been found that PKC phosphorylates Nrf2 at Ser-40 facilitating its release from Keap1-mediated inhibition (Wakabayashi et al., 2010; Stepkowski and Kruszewski, 2011).
B3. The redox signaling "model of two Nrf2 pools"
Multiple NLS/NES (Nuclear localisation signal/ nuclear export signal) motifs have been identified in the Nrf2 sequence. These include three NLS motifs (bNLS, NLSN and NLSc) and two NES motifs (NESTA and NESZIP) but only the NESTA motif has been found to be redox-sensitive. Specifically, the NESTA motif has been shown to display a graded response to oxidative stress, implying that it can not only sense the presence of reactive oxidative species, but it also has the ability to transmit the oxidative stress "intensity" to the nucleus in order to up-regulate the transcription of ARE-genes accordingly.
Based on these observations, Nrf2 has been proposed as a direct redox-sensor. Specifically, under basal condition a dynamic balance can be observed as the combined nuclear exporting forces of NESTA and NESZIP counteract the combined nuclear importing force of the bNLS, NLSN and NLSc leading to a whole-cell distribution of Nrf2. However, under oxidative stress the NESTA is functionally disabled, and the driving force of NLSs becomes dominant and favors the nuclear localization of Nrf2.
The NLS/NES motifs and their role in activation of Nrf2 have led to the hypothesis for Keap1-independent Nrf2 signaling. Nevertheless, this model does not exclude Keap1 involvement in redox signaling. Consequently, a new model has been proposed that encompasses both Keap1-dependent and Keap1-independent Nrf2 signaling. This model proposes that in cells there may exist a free-floating pool of Nrf2 (fNrf2) and a Keap1-bound pool of Nrf2 (kNrf2). Under homeostatic conditions there is an equilibrium between synthesis and degradation of Nrf2, such that the fNrf2 pool remains small. But when cells are exposed to oxidative stress, the Nrf2-binding capacity of Keap1 is diminished and the fNrf2 pool is enlarged. As the NESTA of the fNrf2 redox-sensitive pool is disabled by the stress, nuclear localization of Nrf2 is favored (Li and Kong, 2009).
B4. Competitors of Nrf2 for binding to Keap1
It has been demonstrated that the ability of Keap1 to repress Nrf2 can be modulated by proteins that also possess ETGE motifs and thereby compete with Nrf2 for the same binding site in Keap1. For example, dipeptidyl-peptidase 3 (DPP3), IκB kinase β (IKKβ), partner and localizer of BRCA2 (PALB2), phosphoglycerate mutase 5 (PGAM5) and Wilms tumor gene on X chromosome (WTX) contain ETGE motifs that enable them to bind Keap1 and act as competitors of Nrf2 (Hayes and Dinkova-Kostova, 2014).
B5. mTOR signaling and p62-dependent degradation of Keap1
There is also cross-talk between Nrf2-Keap1 signaling and autophagy. It has been shown that in normal cells this interaction serves as a host defence mechanism leading to expression of antioxidant enzymes as well as elimination of cytotoxic products. Keap1 can bind the autophagy cargo receptor p62, which contains an STGE motif similar to the ETGE motif of Nrf2. Following phosphorylation of Ser 351 within its STGE motif by the mammalian target of rapamycin complex (mTORC1), p62 becomes a potent inhibitor of Keap1. p62 is phosphorylated by mTORC1 in the presence of ubiquitinated autophagic cargos, which can occur under oxidative conditions; this in turn favors the binding of Keap1 to the phosphorylated STGE motifs. As a result, Keap1 is sequestrated in autophagy cargos in a p62-dependent manner, allowing Nrf2 to be stabilized and to accumulate in the nucleus to induce cytoprotective enzymes (Komatsu et al., 2010; Ichimura et al., 2013; Lamming and Sabatini, 2013).
B6. Cross-talk between p53/p21 and the Nrf2 pathway
The p53 tumor suppressor protein regulates several intracellular procedures including gene transcription and induction of apoptosis. It has been demonstrated that p53 is implicated in the regulation of the Nrf2-mediated oxidative response in a dual manner: under low or mild levels of oxidative stress, p53 promotes the stabilization of Nrf2 and its subsequent nuclear accumulation through the transcriptional activation of p21, and as a result reduces the oxidative burden to promote cell survival. p21 stabilizes Nrf2 due to the existence of a KRR motif within the p21 sequence which interacts with the DLG motif of Nrf2 inhibiting its binding to Keap1. On the other hand, under conditions of high or sustained levels of oxidative stress, Nrf2-mediated cell survival is suppressed, and high activity levels of p53 induce apoptosis to prevent tumorigenesis (Chen et al., 2009; Chen W et al., 2012).
B7. Competitive binding of BRCA1 to Nrf2
The ability of Keap1 to repress Nrf2 can be diminished by the competitive binding of breast cancer protein BRAC1, thereby preventing Keap1 from simultaneously binding to the ETGE motif of Nrf2 (Gorrini et al., 2013).
B8. Acetylation of Nrf2 by p300/CBP
It has been found that acetylation of the Neh1 domain of Nrf2 can increase the binding affinity of Nrf2-Maf heterodimers for ARE sequences. p300/CBP acetylates lysine residues of the Neh1 domain and enhances the interaction between Nrf2 and ARE sequence of antioxidant genes promoter resulting in induction of the respective genes' transcription (Sun et al., 2009).
Other mechanistic models which have been proposed for Nrf2 stabilization and activation include the oxidation-induced dissociation of the CRLkeap1 complex, and the nucleocytoplasmic shuttling of Keap1 (Rachakonda et al., 2008; Eggler et al., 2009; Baird and Dinkova-Kostova, 2011).

Repression of Nrf2 signaling
A. Transcriptional repression of the NFE2L2 gene
A CpG island has been identified in the 5' flanking region of the NFE2L2 gene that extends to position -1175. The first 5 CpGs in this CpG island are found to be hypermethylated in prostate cancer samples and prostate cancer cell lines compared to normal prostate issues and cells. This hypermethylation leads to repression of NFE2L2 gene expression, potentially favouring tumorigenesis (Yu et al., 2010).
B. Post-transcriptional repression of Nrf2
At the post-transcriptional level, various micro RNAs (miRNAs) have been identified to interact with the Nrf2 mRNA resulting in repression of Nrf2 expression, including miR-27a, miR-28, miR-93, miR-142-5p, miR144 and miR-153 (Hayes and Dinkova-Kostova, 2014).
C. Post-translational repression of Nrf2
C1. CRLkeap1 complex-mediated degradation of Nrf2
As mentioned, the CRLkeap1 complex is responsible for the ubiquitination and 26S degradation of Nrf2 under normal conditions. Keap1 acts as an adaptor protein to mediate the interaction between Nrf2 and the Cul3 E3-ligase enyme, resulting in ubiquitination of lysines residues of the region located between the ETGE and DLG motifs in the Neh2 domain. Thereafter, ubiquitinated Nrf2 undergoes degradation by the 26S proteosome. It has been reported that the Nedd8 molecule serves as a factor of stabilization of the CRLkeap1 complex, and that the removal of Nedd8 by the CSN signalosome causes disruption of the complex and inhibition of Nrf2 ubiquitination. CAND1 is a mediator protein that can also block the degradation process of Nrf2 (Villeneuve et al., 2010).
C2. Crm1-dependent nuclear export and β-TrCP-dependent degradation of Nrf2
Nrf2 degradation by Keap1 is mediated by interaction via the Nrf2 Neh2 ETGE and DLG motifs. Nevertheless, in Nrf2 proteins mutant for the ETGE and DLG motifs, it has been observed that the Neh6 domain accounts for some of the residual instability of Nrf2 in a Keap1-independent way. Specifically, it has been shown that the DSGIS and DSAPGS motifs located within the Neh6 domain serve as binding sites through which Nrf2 binds with β-TrCP. β-TrCP has the ability to target Nrf2 for ubiquitination and degradation through a Skp1-Cul1-Rbx1/ Roc1 ubiquitin ligase complex; in vitro experiments with fibroblasts where β-TrCP is knocked down have shown increased Nrf2 protein levels.
This mechanism participates in the post-induction regulation of Nrf2 activity. The serine/threonine kinase GSK-3 controls the activity of the nuclear kinase Fyn which in turn phosphorylates Tyr568 of Nrf2 and promotes its Crm1 (exportin)-mediated export from the nucleus. GSK-3-mediated Fyn phosphorylation also causes an increase of the DSGIS degron activity in the Neh6 domain. The latter results in β-TrCP binding to the Neh6 domain of Nrf2 and consequently in β-TrCP-mediated Nrf2 degradation (Jain and Jaiswal, 2007; Chowdhry et al., 2013).
C3. Repression of Nrf2 by CRIF1, SIAH2 and RNF4
The CR6-interacting factor 1 (CRIF1) can promote the ubiquitination of Nrf2 through its interaction with both the N-terminal Neh2 and C-terminal Neh3 domains of Nrf2. The physiological circumstances when CRIF1 represses Nrf2 activity remain obscure.
During hypoxia, it has been observed that SIAH2 can lead to Nrf2 ubiquitination in a Neh2-independent manner. Further work is required to elucidate the basis of interaction between SIAH2 and Nrf2 and the conditions that regulate it.
It has been reported that small ubiquitin-like modifiers 1 and 2 (SUMO-1, SUMO-2) polysumoylate Nrf2 in promyelocytic leukemia nuclear bodies. The polysumoylated Nrf2 (pNrf2) translocates into the nucleus where SUMO-specific RING finger protein 4 (RNF4) ubiquitinates the pNrf2 leading it to degradation within the nucleus (Hayes and Dinkova-Kostova, 2014).
C4. Negative feedback loops regulating Nrf2
In vitro experiments have shown that antioxidant treatment can induce the expression of Keap1, suggesting a possible role of Nrf2 in the regulation of Keap1 expression. Keap1 has three ARE sequences within its promoter, of which one ARE on the reverse strand (position -46) has been demonstrated to be functional in facilitating KEAP1 gene transcription. Thus, it has been suggested that Nrf2 can control its own degradation by binding to the Keap1 ARE(-46) and thereby inducing KEAP1 transcription. In other words, there exists an autoregulatory loop in which Nrf2 controls Keap1 at the transcriptional level and Keap1 regulates Nrf2 at the post-translational level (Lee et al., 2007).
Similarly, it has been observed that Nrf2 regulates the expression of the Cul3 and Rbx1 genes. The Cul3 and Rbx1 proteins are constituents of the CRLkeap1 complex which is responsible for the ubiquitination of Nrf2. Specifically, it has been found that both the Cul3 gene promoter and the Rbx1 gene promoter contain one functional ARE, and that Nrf2 acts in an autoregulatory way by binding to these AREs to regulate the expression of the Cul3 and Rbx1 genes (Kaspar and Jaiswal, 2010).
In addition, there is evidence that Nrf2 is implicated in the expression of genes encoding 26S proteasome subunits, presumably in order to increase the proteasome-dependent removal of oxidatively damaged proteins. Therefore, it has been proposed that Nrf2 may regulate this negative autoregulatory feedback loop via the proteasome to restore its levels to the basal state after the removal of oxidative stimuli (Chapple et al., 2012).
Furthermore, it is known that Bach1 competes with Nrf2 for binding to the ARE-sequence of Nrf2-regulated genes. It has been demonstrated that Bach1 transcript variant 2 has an intronic ARE sequence (position +1411) and can be a transcriptional target gene of Nrf2 (negative autoregulatory feedback mechanism) (Jyrkkänen et al., 2011).
Finally, it has been recently discovered in cancer cell lines that retinoid X receptor α (RXRα) serves as an inhibitor of Nrf2 that regulates Nrf2 activity through a direct interaction with Neh7 domain, where a RXRα-binding site has been mapped. As the activation of Nrf2 results in upregulation of RXRα, this can form another negative feedback loop for Nrf2 regulation (Wang et al., 2013).

  Schematic overview of the main steps in the regulation of the Keap1-Nrf2 antioxidant response pathway. Adapted from Sykiotis and Bohmann, 2010.
Homology Nrf2 belongs to a family of basic leucine zipper (bZip) transcription factors called cap'n'collar (cnc) proteins. Cnc proteins are defined by the presence of a conserved 43-amino acid cnc domain located N-terminally to the DNA-binding domain (bZip structure) and are conserved in invertebrates and vertebrates but not present in plants or fungi. The best studied cnc proteins are the C. elegans SKN-1 (Skin family member 1), the D. melanogaster Cnc (isoforms B and C), and four vertebrate counterparts: the p45 NFE2 (nuclear factor erythroid-derived 2) and the NFE2-related factors Nrf1, Nrf2 and Nrf3 ("the Nrfs"). In addition, the related transcription factors Bach1 and Bach2 are characterised by the additional presence of a BTB protein interaction domain (Sykiotis and Bohmann, 2010).
Although most Cnc factors are transcriptional activators, Bach1 and Bach2 function mainly (through not exclusively) as transcriptional repressors (figure below). Some of the Cnc proteins have important roles in development; for example, CncB is required for the development of head segments in D. melanogaster. Other family members (including Nrf2) are dispensable for development but rather contribute to the maintenance of cellular homeostasis in response to endogenous or exogenous stressors. In particular, the three Nrfs have broad and partly overlapping expression patterns and function as stress-activated transcription factors (Sykiotis and Bohmann, 2010).


Somatic Somatic mutations of the NFE2L2 gene have been detected in cancers. Mainly missense mutations and in frame insertions/deletions of NFE2L2 localised in the DLG and ETGE motifs of the Neh2 domain cause modifications in Nrf2 protein that lead to impaired interaction of Nrf2 with Keap1, and thereby to constitutive Nrf2 activation. Thus, the Nrf2 pathway is currently believed to have a role not only in cancer prevention via detoxification and maintenance of cellular homeostasis, but also in the cell growth and survival of malignant or premalignant cells. NFE2L2 mutations have been identified in oesophageal squamous cell carcinoma (8/70, 11.4%; 6/32, 18.8%), skin cancer (1/17, 6.3%; 1/22, 4.5%), non-small cell lung carcinoma (NSCLC, 6.9-10.7%), head and neck carcinoma (HN, 13-25%), cervical cancer (1/18, 5.6%) and papillary renal cell carcinoma (2 cases).
Interestingly, lung cancer, and particularly non-small cell lung cancer, has been investigated for NFE2L2 mutations in various patient populations, and in all studies the presence of NFE2L2 mutations was positively correlated with smoking history. In addition, it has been observed that the frequency of NFE2L2 gene mutations is higher in lung squamous cell carcinoma than in lung adenocarcinoma (Shibata et al., 2008a; Kim et al., 2010; Solis et al., 2010; Shibata et al., 2011; Hu et al., 2012; Gañán-Gómez et al., 2013; Ooi et al., 2013).

NFE2L2 polymorphisms
Specific polymorphisms associated with disease risk*
Respiratory disorders
Heterozygosity (T/G) for rs6721961 (T/C/G) has been associated with increased risk of acute lung injury (ALI) in patients with major trauma in Caucasian/African-American and Japanese populations. Paradoxically, in a Japanese cohort, the haplotype (rs2001350T/rs6726395A/ rs1962142A/rs2364722A/rs6721961T) containing the homozygous SNP rs6721961 TT has been correlated with lower annual decline in forced expiratory volume in one second (FEV1), a measure of pulmonary function. In contrast, the rs6726395 G allele showed association with higher annual decline of FEV1 induced by cigarette smoking in Japanese. Furthermore, a haplotype containing rs35652124 C, rs6706649 C, rs6721961 G and GGC4 (a repeat polymorphism) has been proposed as a predictor factor of increased respiratory failure development in German patients with chronic obstructive pulmonary disease (COPD). A further study in a Netherlands population showed correlations between rs1806649 C and reduced COPD mortality, and between the rs2364723 CC and reduced FEV1. In a Hungarian population of childhood asthma, rs6721961 T and rs2588882 G have been inversely correlated with the infection-induced asthma.
Cardiovasular disorders
The rs6721961 TT genotype has been associated with higher systolic and diastolic blood pressure in Japanese haemodialysis patients than the CC or CT genotypes. Similarly, haemodialysis patients with the rs35652124 TT genotype had higher diastolic blood pressure and higher cardiovascular mortality than CC or CT carriers. Finally, in a Netherlands population, it has been demonstrated that carriers of the rs2364723 (G/C) minor G allele showed lower triglyceride levels and reduced risk of cardiovascular mortality.
Gastrointestinal disorders
The rs6706649 C and rs35652124 C SNPs have higher frequency in Japanese patients with ulcerative colitis, and their presence has been correlated with a chronic continuous disease phenotype. In Helicobacter pylori-infected patients, the rs6706649C/rs35652124C and rs6706649C/rs35652124T haplotypes have been correlated with increased and decreased risk, respectively, of CpG methylation; rs6706649C/rs35652124T carriers with negative Helicobacter pylori test showed reduced risk of gastric cancer.
Autoimmune disorders
In a Mexican Mestizo population it was found that lupus nephritis in women was significantly associated with presence of the heterozygous rs35652124 (C/T).
Breast cancer
Homozygosity for rs6721961 (TT) or rs2706110 (TT) has been associated with increased risk of breast cancer in a Finish population. Moreover, presence of the rs6721961 T allele together with the intronic rs1962142 A allele was associated with reduced Nrf2 expression in breast cancer tissue. In a study of a Finish population, Nrf2 rs2886182 (T/C) rare homozygous genotype TT has been significantly associated with poorer survival and recurrence-free survival in patients with breast cancer that had received adjuvant chemotherapy, and with poorer survival in patients with breast cancer that had undergone postoperative radiotherapy.
Venous thromboembolism
In postmenopausal women the rs6721961 (T allele) increased the risk of venous thromboembolism after oral estrogen therapy.
Neurodegenerative diseases
In Swedish populations, a protective effect against Parkinson's disease has been detected for a haplotype containing promoter SNPs rs7557529C/ rs35652124T/ rs6706649C/ rs6721961G as well as intronic SNPs rs2886161T/ rs1806649T/ rs2001350T/ rs10183914T) (Yamamoto et al., 2004; Marzec et al., 2007; Arisawa et al., 2008; Siedlinski et al., 2009; Masuko et al., 2011; Hartikainen et al., 2012; Cho, 2013; Figarska et al., 2014; Shimoyama et al., 2014).
* The nucleotides for each SNP correspond to the map on chr. 2, and are thus complementary to the gene sequence (NFE2L2 lies on the reverse strand).

Implicated in

Entity Various cancers
Note The dual role of Nrf2: NFE2L2 has been found to have both cancer chemopreventive activity (by protecting cells from carcinogen-induced damage and transformation) and oncogenic activity (by conferring a survival advantage to pre-malignant or malignant cells). Thus, on the one hand, activation of Nrf2 upregulates various conjugating enzymes for the detoxification of chemical carcinogens and protects from carcinogenicity, mutagenicity and other forms of toxicity. Experimental disruption of Nrf2 is associated with increased susceptibility of cells to carcinogens. The chemopreventive properties of Nrf2 have been demonstrated in several experimental models of cancer including colon, bladder, lung, stomach, breast, skin and liver cancer. Importantly, inducers of Nrf2 pathway are being tested in clinic trials for cancer chemoprevention.
On the other hand, in various cancers Nrf2 protein abundance and activity have been found to be increased, suggesting a role in tumour growth and survival. Gain of function somatic mutations in NFE2L2 gene which lead to disruption of the Nrf2-Keap1 binding interface complex result in upregulation of Nrf2 activity. These mutations have been identified in NSCLC, oesophageal squamous cell carcinoma, malignant melanoma, skin squamous cell carcinoma, head and neck carcinoma and cervical cancer.
In addition, it has been reported that an indirect way of upregulation of Nrf2 activity is the loss of function KEAP1 somatic mutations. These mutations have been detected in various types of cancer [lung cancer (NSCLC), thyroid papillary cancer, oesophageal cancer, gastric adenocarcinoma, hepatocellular and cholangiocellular carcinoma, gallbladder cancer, colorectal adenocarcinoma, caecum carcinoma, breast ductal carcinoma and adenocarcinoma, endometrial adenocarcinoma, ovarian serous cancer and epithelial cancer, prostate adenocarcinoma, kidney and urinary tract cancer, malignant melanoma and neuroblastoma].
Another mechanism of constitutive activation of Nrf2 in cancer cells is the silence of KEAP1 gene caused by hypermethylation of KEAP1 gene promoter. This silencing mechanism of KEAP1 gene has been detected in human lung cancer tissue cells (squamous, adenocarcinoma, adenosquamous), lung cancer cell lines, human breast cancer tissues, colorectal cell lines, prostate cancer cell lines, human malignant gliomas and papillary thyroid cancer. Hypermethylation of CUL3 and RBX1 genes as well as CUL3, RBX1 and KEAP1 copy number losses have been proposed as further Nrf2 activation mechanisms in papillary thyroid carcinoma.
Moreover, Nrf2 expression and activation can be induced by Nrf2 cross-talk with other signalling pathways. Specifically, it has been demonstrated that in acute myeloid leukaemia (AML) Nrf2 overexpression is driven by abnormal expression of Nuclear Factor-κB (NF-κB). In addition, in NSCLC cell lines constitutive activation of mutant epidermal growth factor receptor (EGFR) and RagD-mediated activation of cause overactivation of Nrf2 as well as Nrf2-mediated resistance to EGFR-tyrosine kinase inhibitor and m-TOR inhibitor, respectively. In renal cancer cells, Nrf2 activity has been found to be increased by downregulation of E-cadherin which normally forms a quanternary complex with Nrf2, Keap1 and β-catenin and facilitates Keap1-mediated ubiquitination of Nrf2. Finally, it has been observed that transcriptional coactivator amplified in breast cancer 1 (AIB1) stimulates Nrf2 activation in cholangiocarcinoma cells inducing tumour proliferation and chemoresistance. Thus, AIB1 has been proposed as a Nrf2 coactivator.
In summary, the upregulation of Nrf2 has antioxidant as well as cytoprotective effect in cancer cells. Especially, cytoprotective activity of Nrf2 can be exploited by cancer cells not only to face their oxidant tumour microenvironment, but also confer chemo- or/and radio- resistance during anticancer therapies. Consequently, suppression of Nrf2 activity in cancer cells inhibits tumour growth and enhances the efficacy of chemotherapeutic agents. Therefore, Nrf2 could be a target not only for cancer chemoprevention (via activating compounds) but also for cancer treatment (via inhibitors) (Shibata et al., 2008a; Shibata T. et al, 2008b; Wang et al., 2008; Chen et al., 2010; Solis et al., 2010; Yoo et al., 2010; Kim et al., 2010; Shibata et al., 2010; Wang et al., 2010; Muscarella et al., 2011; Shibata et al., 2011; Chen Q et al., 2012; Guo et al., 2012; Hanada et al., 2012; Hu et al., 2012; Kim et al., 2012; Liao et al., 2012; Sporn and Liby, 2012; Yamadori et al., 2012; Barbano et al., 2013; Gañán-Gómez et al., 2013; Martinez et al., 2013; Shelton and Jaiswal, 2013; Shin et al., 2013; Ziros et al., 2013; Zhang et al., 2013; Funes et al., 2014; Gorrini et al., 2014; Ji et al., 2014; Onodera et al., 2014; Schultz et al., 2014).
Disease Lung cancer, thyroid cancer, ovarian cancer, breast cancer, prostate cancer, endometrial cancer, cervical cancer, gastric cancer, oesophagus cancer, colorectal cancer, gallbladder cancer, liver cancer, skin cancer, acute myeloid leukemia.
Exogenous Nrf2 inducers.
Entity Airway diseases
Note Oxidative stress has been associated with the pathogenesis of many acute and chronic airway disorders.
ALI and its severe form ARDS are characterised by severe systemic hypoxemia in seriously ill patients. Hypoxemia is associated with production of excessive ROS, and thus oxidative stress is a major contributor to the pathogenesis of ALI. In such hypoxic situations oxygen is one of the most commonly used supplemental therapeutic agents. However, oxygen supplementation-induced hyperoxia can also cause lung injury and airway inflammation. Nrf2 has been proposed as a hyperoxia susceptibility gene that modulates ALI in vivo.
Emphysema is characterised by loss of pulmonary elasticity as a result of permanent alveolar wall destruction and represents the alveolar lesion in COPD. Cigarette smoke is a major contributor to emphysema and COPD pathogenesis. Chronic exposure to cigarette smoke in Nrf2 knockout (KO) mice causes more severe emphysema than in wild type mice. This is associated with greater levels of inflammation, oxidative stress and endothelial and epithelial cell apoptosis in the Nrf2 KO mice.
LPS (lipo-polysaccharide)-induced septic shock in Nrf2 KO mice results in premature mortality in comparison with wild type mice, and non-lethal exposure to LPS results in greater lung inflammation and injury in Nrf2 KO mice.
Regarding asthma disease, it has been observed that the disruption of Nrf2 can cause severe airway inflammation and airway hyper-responsiveness in mouse models of asthma.
IPF is a fibroproliferative disease thought to be triggered by repeated alveolar epithelial cell injury. Rodent models of bleomycin-induced lung fibrosis have been used to study IPF. The pulmonary fibrogenic effects of bleomycin are antagonised by antioxidant enzymes like SODs in rodents. Moreover, it has been noticed that Nrf2 KO mice treated with bleomycin had elevated levels of TGF-β, the main fibrogenic factor.
Finally, it has been reported that Nrf2 has a protective role against airway infection by RSV in mice (Reddy, 2008; Cho and Kleeberger, 2010).
Disease Acute lung injury (ALI), emphysema/chronic obstructive pulmonary disease (COPD), lung disorder during sepsis [LPS (lipo-polysaccharide)-induced septic shock], asthma/allergic airway diseases, idiopathic pulmonary fibrosis (IPF), viral airway disease (RSV - respiratory syncytial virus)
Entity Cardiovascular disease
Note Nrf2 is expressed in the cardiovascular system (heart and blood vessels), and Nrf2 signaling is implicated in the regulation of vascular homeostasis and in the prevention of cardiac hypertrophy and heart failure via suppression of oxidative stress. Although Nrf2 has been proposed as a therapeutic target in cardiovascular diseases like atherosclerosis, there is some evidence that reveal the role of Nrf2 as pro-atherogenic factor via a different mechanism. Nevertheless, modulation of Nrf2 has been supported for the prevention and the treatment of heart diseases (Sussan et al., 2008; Koenitzer and Freeman, 2010; Freigang et al., 2011).
Entity Diabetes, diabetic nephropathy, diabetic neuropathy
Note Nrf2-mediated expression of endogenous cytoprotective enzymes and other antioxidant molecules has been shown to be an adaptive defence mechanism against high glucose-induced oxidative damage in diabetes. Diabetic nephropathy and neuropathy have been studied in correlation with the activity of Nrf2 pathway, and it has been found that Nrf2 exerts a protective role against these long-term complications of diabetes (Jiang et al., 2010; Cheng et al., 2011; Negi et al., 2011).
Entity Obesity/metabolic syndrome
Note While it appears that the Nrf2 pathway is a regulator of energy metabolism, its precise effects and the underlying mechanisms are still controversial. In some contexts Nrf2 is protective and high-fat diet-induced obesity, while in others it is a contributing factor to metabolic disease. Nrf2 can induce several metabolic regulators in adipose tissue and liver such as PPARγ, C/EBPβ and AhR, and it can repress others such as FGF21. The exact mechanisms by which Nrf2 cross-talks with these factors are the focus of ongoing research (Chartoumpekis and Kensler, 2013).
Entity Liver and gastrointestinal diseases
Note Nrf2 has been demonstrated to be a key factor dictating susceptibility to oxidative and chemical-induced injury in the gastrointestinal system. In vivo experiments have revealed that Nrf2 KO mice are more susceptible to acetaminophen-induced hepatocellular injury, benzo(a)pyrene-induced tumour formation, and Fas- and TNFα-mediated hepatocellular apoptosis. In addition, Nrf2 may be important in protecting against liver fibrosis and gallstone development. Regarding intestinal diseases, it has been suggested that Nrf2 plays an important role in the maintenance of intestinal integrity and may serve as novel target for therapies to prevent or treat Crohn's disease or ulcerative colitis (Aleksunes and Manautou, 2007).
Disease Drug-induced hepatotoxicity, hepatocellular apoptosis, liver fibrosis, gallstone disease, bowel diseases (Crohn's disease and ulcerative colitis), chemical carcinogenesis in the gastrointestinal system
Entity Neurodegenerative diseases
Note Oxidative stress is involved in the pathogenesis of a wide range of chronic neurodegenerative diseases such as AD, PD and HD.
AD is characterised by increased accumulation in the brain of neurotoxic and oxidative elements such as iron. In addition, increased oxidative damage of proteins and lipid peroxidation has been detected in the brain of AD patients. Reactive astrocytes and activated microglia contribute to the oxidative stress observed in AD brain. The expression profile of Nrf2 and ARE-regulated proteins in AD brain tissue supports the hypothesis that Nrf2 signalling may be involved in the early stages of AD.
PD, the second most common neurodegenerative disease after AD, is characterised by the preferential loss of dopaminergic neurons in the substantia nigra. Mitochondrial dysfunction and neuroinflammation in PD play a crucial role in PD pathogenesis and the subsequent oxidative stress has been suggested to be responsible for the degeneration of nigral dopaminergic neurons. Nrf2 pathway may have a neuroprotective effect on PD and its activation may be a novel therapeutic approach.
HD is a rare neurodegenerative disorder inherited in an autosomal dominant manner. Work in mouse model has shown that Nrf2 can have neuroprotective roles against HD and might be a novel treatment target for HD. Furthermore, it has been reported that Nrf2 can also potentially protect from neuronal damage in other neurological diseases such as ALS, Freidrich's ataxia, Down syndrome, multiple sclerosis, traumatic brain injury and cerebral haemorrhages (Ramsey et al., 2007; Calabrese et al., 2008; de Vries et al., 2008; Jazwa et al., 2011; Tufekci et al., 2011).
Disease Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease(HD), Freidrich's ataxia, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Down syndrome, traumatic brain injury, cerebral haemorrhage
Entity Rheumatoid arthritis
Note ROS play an important role in the pathogenesis of rheumatoid arthritis (RA), and antioxidant substances and enzymes reduce cartilage damage in animal models of RA. It has been reported that a deficiency in Nrf2-mediated antioxidant defences plays a central role in pathogenesis of RA. Oxidative stress is one of the factors that contribute to RA, and Nrf2 could play an important role in alleviating its effects (Wruck et al., 2011).
Entity Uveitis
Note Uveitis is an inflammatory eye disease that can cause blindness. The main characteristic of uveitis is an inappropriate innate immune response resulting in local tissue injury. ROS production with secretion of inflammatory cytokines and leukocytes infiltration has been documented in a model of LPS-induced uveitis. In this model, due to an inadequate activation of Nrf2, the induction of antioxidant and anti-inflammatory responses is also incomplete. Potentiation of the antioxidant response with an Nrf2-inducing compound led to increased enzyme expression of protective enzymes, reduced cytokine expression, and decreased leukocyte adhension, suggesting Nrf2 as a potential therapeutic target in uveitis (Nagai, 2009).
Entity Aging
Note A popular "hypothesis" about the causes of aging is the "free radical theory", which considers aging as the result of progressive damage to macromolecules and cellular structures caused by exposure to endogenous and exogenous pro-oxidant substances, notably free radicals. Nrf2 and its homologues in invertebrate models of aging have been shown to exert anti-aging and pro-longevity functions. Nevertheless, Nrf2 activity generally declines with age, and this decline is associated with decreased expression and/or inducibility of antioxidant genes. Overall, it is believed that, if properly fine-tuned, the Nrf2 pathway can have life span-extending effects, and can therefore be a target for promoting longevity and extending the disease-free period of life (the "health span") (Sykiotis and Bohmann, 2010).

To be noted



Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease.
Aleksunes LM, Manautou JE.
Toxicol Pathol. 2007 Jun;35(4):459-73. (REVIEW)
PMID 17562481
Nrf2 gene promoter polymorphism and gastric carcinogenesis.
Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Okubo M, Hirata I, Nakano H.
Hepatogastroenterology. 2008 Mar-Apr;55(82-83):750-4.
PMID 18613447
The cytoprotective role of the Keap1-Nrf2 pathway.
Baird L, Dinkova-Kostova AT.
Arch Toxicol. 2011 Apr;85(4):241-72. doi: 10.1007/s00204-011-0674-5. Epub 2011 Mar 2. (REVIEW)
PMID 21365312
Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element.
Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, Motterlini R.
Biochem J. 2003 May 1;371(Pt 3):887-95.
PMID 12570874
Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.
Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P.
Epigenetics. 2013 Jan;8(1):105-12. doi: 10.4161/epi.23319. Epub 2012 Dec 18.
PMID 23249627
Carotenoids activate the antioxidant response element transcription system.
Ben-Dor A, Steiner M, Gheber L, Danilenko M, Dubi N, Linnewiel K, Zick A, Sharoni Y, Levy J.
Mol Cancer Ther. 2005 Jan;4(1):177-86.
PMID 15657364
Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity.
Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E.
Neurochem Res. 2008 Dec;33(12):2444-71. doi: 10.1007/s11064-008-9775-9. Epub 2008 Jul 16. (REVIEW)
PMID 18629638
Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity.
Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B.
Food Chem Toxicol. 2002 Aug;40(8):1155-63. (REVIEW)
PMID 12067578
Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging.
Chapple SJ, Siow RC, Mann GE.
Int J Biochem Cell Biol. 2012 Aug;44(8):1315-20. doi: 10.1016/j.biocel.2012.04.021. Epub 2012 May 7. (REVIEW)
PMID 22575091
New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome.
Chartoumpekis DV, Kensler TW.
Curr Diabetes Rev. 2013 Mar 1;9(2):137-45. (REVIEW)
PMID 23363332
Nrf2 expression in endometrial serous carcinomas and its precancers.
Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W.
Int J Clin Exp Pathol. 2010 Dec 24;4(1):85-96.
PMID 21228930
Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q, Li W, Wan Y, Xia X, Wu Q, Chen Y, Lai Z, Yu C, Li W.
Hepatology. 2012 Jun;55(6):1820-9. doi: 10.1002/hep.25549. Epub 2012 Apr 25.
PMID 22213475
Does Nrf2 contribute to p53-mediated control of cell survival and death?
Chen W, Jiang T, Wang H, Tao S, Lau A, Fang D, Zhang DD.
Antioxid Redox Signal. 2012 Dec 15;17(12):1670-5. doi: 10.1089/ars.2012.4674. Epub 2012 Jun 11.
PMID 22559194
Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response.
Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD.
Mol Cell. 2009 Jun 26;34(6):663-73. doi: 10.1016/j.molcel.2009.04.029.
PMID 19560419
Regulation of the Nrf2 antioxidant pathway by microRNAs: New players in micromanaging redox homeostasis.
Cheng X, Ku CH, Siow RC.
Free Radic Biol Med. 2013 Sep;64:4-11. doi: 10.1016/j.freeradbiomed.2013.07.025. Epub 2013 Jul 21. (REVIEW)
PMID 23880293
Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway.
Cheng X, Siow RC, Mann GE.
Antioxid Redox Signal. 2011 Feb 1;14(3):469-87. doi: 10.1089/ars.2010.3283. Epub 2010 Aug 20. (REVIEW)
PMID 20524845
Nrf2 protects against airway disorders.
Cho HY, Kleeberger SR.
Toxicol Appl Pharmacol. 2010 Apr 1;244(1):43-56. doi: 10.1016/j.taap.2009.07.024. Epub 2009 Jul 29. (REVIEW)
PMID 19646463
Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY.
Oxid Med Cell Longev. 2013;2013:286524. doi: 10.1155/2013/286524. Epub 2013 Jul 10. (REVIEW)
PMID 23936606
Nrf2 is controlled by two distinct ?-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity.
Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD.
Oncogene. 2013 Aug 8;32(32):3765-81. doi: 10.1038/onc.2012.388. Epub 2012 Sep 10.
PMID 22964642
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA.
Nature. 2011 Jul 6;475(7354):106-9. doi: 10.1038/nature10189.
PMID 21734707
Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants.
Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK.
J Biol Chem. 2005 Apr 29;280(17):16891-900. Epub 2005 Feb 24.
PMID 15734732
Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.
Eggler AL, Small E, Hannink M, Mesecar AD.
Biochem J. 2009 Jul 29;422(1):171-80. doi: 10.1042/BJ20090471.
PMID 19489739
NFE2L2 polymorphisms, mortality, and metabolism in the general population.
Figarska SM, Vonk JM, Boezen HM.
Physiol Genomics. 2014 Jun 15;46(12):411-7. doi: 10.1152/physiolgenomics.00178.2013. Epub 2014 May 1.
PMID 24790085
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
Filipowicz W, Bhattacharyya SN, Sonenberg N.
Nat Rev Genet. 2008 Feb;9(2):102-14. doi: 10.1038/nrg2290. (REVIEW)
PMID 18197166
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis.
Freigang S, Ampenberger F, Spohn G, Heer S, Shamshiev AT, Kisielow J, Hersberger M, Yamamoto M, Bachmann MF, Kopf M.
Eur J Immunol. 2011 Jul;41(7):2040-51. doi: 10.1002/eji.201041316. Epub 2011 Jun 8.
PMID 21484785
Oncogenic transformation of mesenchymal stem cells decreases Nrf2 expression favoring in vivo tumor growth and poorer survival.
Funes JM, Henderson S, Kaufman R, Flanagan JM, Robson M, Pedley B, Moncada S, Boshoff C.
Mol Cancer. 2014 Feb 3;13:20. doi: 10.1186/1476-4598-13-20.
PMID 24491031
Oncogenic functions of the transcription factor Nrf2.
Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G.
Free Radic Biol Med. 2013 Dec;65:750-64. doi: 10.1016/j.freeradbiomed.2013.06.041. Epub 2013 Jun 29.
PMID 23820265
Diallyl sulfide induces heme oxygenase-1 through MAPK pathway.
Gong P, Hu B, Cederbaum AI.
Arch Biochem Biophys. 2004 Dec 15;432(2):252-60.
PMID 15542064
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML.
J Exp Med. 2013 Jul 29;210(8):1529-44. doi: 10.1084/jem.20121337. Epub 2013 Jul 15.
PMID 23857982
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.
PMID 24567396
A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells.
Guo D, Wu B, Yan J, Li X, Sun H, Zhou D.
Biochem Biophys Res Commun. 2012 Nov 9;428(1):80-5. doi: 10.1016/j.bbrc.2012.10.010. Epub 2012 Oct 6.
PMID 23047008
Methylation of the KEAP1 gene promoter region in human colorectal cancer.
Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S, Saijo Y.
BMC Cancer. 2012 Feb 13;12:66. doi: 10.1186/1471-2407-12-66.
PMID 22325485
Avicinylation (thioesterification): a protein modification that can regulate the response to oxidative and nitrosative stress.
Haridas V, Kim SO, Nishimura G, Hausladen A, Stamler JS, Gutterman JU.
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10088-93.
PMID 16030151
Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer.
Hartikainen JM, Tengstrom M, Kosma VM, Kinnula VL, Mannermaa A, Soini Y.
Cancer Res. 2012 Nov 1;72(21):5537-46. doi: 10.1158/0008-5472.CAN-12-1474. Epub 2012 Sep 10.
PMID 22964583
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism.
Hayes JD, Dinkova-Kostova AT.
Trends Biochem Sci. 2014 Apr;39(4):199-218. doi: 10.1016/j.tibs.2014.02.002. Epub 2014 Mar 16.
PMID 24647116
Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks.
Hirotsu Y, Katsuoka F, Funayama R, Nagashima T, Nishida Y, Nakayama K, Engel JD, Yamamoto M.
Nucleic Acids Res. 2012 Nov 1;40(20):10228-39. doi: 10.1093/nar/gks827. Epub 2012 Sep 10.
PMID 22965115
Mutation of the Nrf2 gene in non-small cell lung cancer.
Hu Y, Ju Y, Lin D, Wang Z, Huang Y, Zhang S, Wu C, Jiao S.
Mol Biol Rep. 2012 Apr;39(4):4743-7. doi: 10.1007/s11033-011-1266-4. Epub 2011 Oct 1.
PMID 21964605
Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy.
Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M.
Mol Cell. 2013 Sep 12;51(5):618-31. doi: 10.1016/j.molcel.2013.08.003. Epub 2013 Sep 5.
PMID 24011591
Redox regulation of the transcriptional repressor Bach1.
Ishikawa M, Numazawa S, Yoshida T.
Free Radic Biol Med. 2005 May 15;38(10):1344-52.
PMID 15855052
Nuclear import and export signals in control of Nrf2.
Jain AK, Bloom DA, Jaiswal AK.
J Biol Chem. 2005 Aug 12;280(32):29158-68. Epub 2005 May 17.
PMID 15901726
GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2.
Jain AK, Jaiswal AK.
J Biol Chem. 2007 Jun 1;282(22):16502-10. Epub 2007 Apr 2.
PMID 17403689
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, Cuadrado A.
Antioxid Redox Signal. 2011 Jun 15;14(12):2347-60. doi: 10.1089/ars.2010.3731. Epub 2011 Mar 28.
PMID 21254817
Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival.
Ji L, Wei Y, Jiang T, Wang S.
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1124-31. eCollection 2014.
PMID 24695690
The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.
Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD.
Diabetes. 2010 Apr;59(4):850-60. doi: 10.2337/db09-1342. Epub 2010 Jan 26.
PMID 20103708
Novel insights into the regulation of antioxidant-response-element-mediated gene expression by electrophiles: induction of the transcriptional repressor BACH1 by Nrf2.
Jyrkkanen HK, Kuosmanen S, Heinaniemi M, Laitinen H, Kansanen E, Mella-Aho E, Leinonen H, Yla-Herttuala S, Levonen AL.
Biochem J. 2011 Dec 1;440(2):167-74. doi: 10.1042/BJ20110526.
PMID 21812759
BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells.
Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I.
J Biol Chem. 2006 May 26;281(21):14654-62. Epub 2006 Mar 27.
PMID 16567799
Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids.
Kansanen E, Jyrkkanen HK, Levonen AL.
Free Radic Biol Med. 2012 Mar 15;52(6):973-82. doi: 10.1016/j.freeradbiomed.2011.11.038. Epub 2011 Dec 13. (REVIEW)
PMID 22198184
An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance.
Kaspar JW, Jaiswal AK.
J Biol Chem. 2010 Jul 9;285(28):21349-58. doi: 10.1074/jbc.M110.121863. Epub 2010 May 7.
PMID 20452971
Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins.
Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD.
Drug Metabol Drug Interact. 2000;17(1-4):3-22. (REVIEW)
PMID 11201301
E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells.
Kim WD, Kim YW, Cho IJ, Lee CH, Kim SG.
J Cell Sci. 2012 Mar 1;125(Pt 5):1284-95. doi: 10.1242/jcs.095422. Epub 2012 Feb 2.
PMID 22302998
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, Lee SH.
J Pathol. 2010 Mar;220(4):446-51. doi: 10.1002/path.2653.
PMID 19967722
Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells.
Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I.
Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L478-88. Epub 2007 Dec 27.
PMID 18162601
Redox signaling in inflammation: interactions of endogenous electrophiles and mitochondria in cardiovascular disease.
Koenitzer JR, Freeman BA.
Ann N Y Acad Sci. 2010 Aug;1203:45-52. doi: 10.1111/j.1749-6632.2010.05559.x. (REVIEW)
PMID 20716282
The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.
Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M.
Nat Cell Biol. 2010 Mar;12(3):213-23. doi: 10.1038/ncb2021. Epub 2010 Feb 21.
PMID 20173742
Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter.
Kwak MK, Itoh K, Yamamoto M, Kensler TW.
Mol Cell Biol. 2002 May;22(9):2883-92.
PMID 11940647
A Central role for mTOR in lipid homeostasis.
Lamming DW, Sabatini DM.
Cell Metab. 2013 Oct 1;18(4):465-9. doi: 10.1016/j.cmet.2013.08.002. Epub 2013 Aug 22. (REVIEW)
PMID 23973332
Nrf2 as a novel molecular target for chemoprevention.
Lee JS, Surh YJ.
Cancer Lett. 2005 Jun 28;224(2):171-84. Epub 2004 Nov 11. (REVIEW)
PMID 15914268
An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance.
Lee OH, Jain AK, Papusha V, Jaiswal AK.
J Biol Chem. 2007 Dec 14;282(50):36412-20. Epub 2007 Oct 9.
PMID 17925401
Molecular mechanisms of Nrf2-mediated antioxidant response.
Li W, Kong AN.
Mol Carcinog. 2009 Feb;48(2):91-104. doi: 10.1002/mc.20465. (REVIEW)
PMID 18618599
Heterodimerization with small Maf proteins enhances nuclear retention of Nrf2 via masking the NESzip motif.
Li W, Yu S, Liu T, Kim JH, Blank V, Li H, Kong AN.
Biochim Biophys Acta. 2008 Oct;1783(10):1847-56. doi: 10.1016/j.bbamcr.2008.05.024. Epub 2008 Jun 9.
PMID 18585411
Cinnamaldehyde inhibits the tumor necrosis factor-alpha-induced expression of cell adhesion molecules in endothelial cells by suppressing NF-kappaB activation: effects upon IkappaB and Nrf2.
Liao BC, Hsieh CW, Liu YC, Tzeng TT, Sun YW, Wung BS.
Toxicol Appl Pharmacol. 2008 Jun 1;229(2):161-71. doi: 10.1016/j.taap.2008.01.021. Epub 2008 Feb 5.
PMID 18304597
NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones.
Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X, Feng Y.
Oncol Rep. 2012 Jun;27(6):1918-24. doi: 10.3892/or.2012.1700. Epub 2012 Feb 28.
PMID 22378150
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB.
Cancer Res. 2005 Jun 1;65(11):4789-98.
PMID 15930299
Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents.
Magesh S, Chen Y, Hu L.
Med Res Rev. 2012 Jul;32(4):687-726. doi: 10.1002/med.21257. Epub 2012 May 1. (REVIEW)
PMID 22549716
Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD, Vucic EA, Pikor LA, Thu KL, Hubaux R, Lam WL.
Mol Cancer. 2013 Oct 20;12(1):124. doi: 10.1186/1476-4598-12-124.
PMID 24138990
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury.
Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR.
FASEB J. 2007 Jul;21(9):2237-46. Epub 2007 Mar 23.
PMID 17384144
An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study.
Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, Hirota T, Tamari M, Hizawa N.
BMC Med Genet. 2011 Jul 20;12:97. doi: 10.1186/1471-2350-12-97.
PMID 21774808
Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes.
Miao W, Hu L, Scrivens PJ, Batist G.
J Biol Chem. 2005 May 27;280(21):20340-8. Epub 2005 Mar 23.
PMID 15790560
Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.
Moi P, Chan K, Asunis I, Cao A, Kan YW.
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9926-30.
PMID 7937919
A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway.
Morimitsu Y, Nakagawa Y, Hayashi K, Fujii H, Kumagai T, Nakamura Y, Osawa T, Horio F, Itoh K, Iida K, Yamamoto M, Uchida K.
J Biol Chem. 2002 Feb 1;277(5):3456-63. Epub 2001 Nov 12.
PMID 11706044
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Muscarella LA, Barbano R, D'Angelo V, Copetti M, Coco M, Balsamo T, la Torre A, Notarangelo A, Troiano M, Parisi S, Icolaro N, Catapano D, Valori VM, Pellegrini F, Merla G, Carella M, Fazio VM, Parrella P.
Epigenetics. 2011 Mar;6(3):317-25. Epub 2011 Mar 1.
PMID 21173573
Nrf2 is a critical modulator of the innate immune response in a model of uveitis.
Nagai N, Thimmulappa RK, Cano M, Fujihara M, Izumi-Nagai K, Kong X, Sporn MB, Kensler TW, Biswal S, Handa JT.
Free Radic Biol Med. 2009 Aug 1;47(3):300-6. doi: 10.1016/j.freeradbiomed.2009.04.033. Epub 2009 May 3.
PMID 19410644
Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes.
Nakamura Y, Yoshida C, Murakami A, Ohigashi H, Osawa T, Uchida K.
FEBS Lett. 2004 Aug 13;572(1-3):245-50.
PMID 15304356
Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.
Namani A, Li Y, Wang XJ, Tang X.
Biochim Biophys Acta. 2014 Sep;1843(9):1875-85. doi: 10.1016/j.bbamcr.2014.05.003. Epub 2014 May 20. (REVIEW)
PMID 24851839
Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle.
Negi G, Kumar A, Joshi RP, Sharma SS.
Biochem Biophys Res Commun. 2011 Apr 29;408(1):1-5. doi: 10.1016/j.bbrc.2011.03.087. Epub 2011 Mar 31. (REVIEW)
PMID 21439933
NRF2 immunolocalization in human breast cancer patients as a prognostic factor.
Onodera Y, Motohashi H, Takagi K, Miki Y, Shibahara Y, Watanabe M, Ishida T, Hirakawa H, Sasano H, Yamamoto M, Suzuki T.
Endocr Relat Cancer. 2014 Feb 27;21(2):241-52. doi: 10.1530/ERC-13-0234. Print 2014 Apr.
PMID 24302665
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, Furge KA.
Cancer Res. 2013 Apr 1;73(7):2044-51. doi: 10.1158/0008-5472.CAN-12-3227. Epub 2013 Jan 30.
PMID 23365135
Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3.
Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML.
Chem Res Toxicol. 2008 Mar;21(3):705-10. doi: 10.1021/tx700302s. Epub 2008 Feb 6.
PMID 18251510
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice.
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5.
PMID 11248092
Expression of Nrf2 in neurodegenerative diseases.
Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL.
J Neuropathol Exp Neurol. 2007 Jan;66(1):75-85.
PMID 17204939
The antioxidant response element and oxidative stress modifiers in airway diseases.
Reddy SP.
Curr Mol Med. 2008 Aug;8(5):376-83. (REVIEW)
PMID 18691064
The high Nrf2 expression in human acute myeloid leukemia is driven by NF-?B and underlies its chemo-resistance.
Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ.
Blood. 2012 Dec 20;120(26):5188-98. doi: 10.1182/blood-2012-04-422121. Epub 2012 Oct 17.
PMID 23077289
Carnosic acid protects neuronal HT22 Cells through activation of the antioxidant-responsive element in free carboxylic acid- and catechol hydroxyl moieties-dependent manners.
Satoh T, Izumi M, Inukai Y, Tsutsumi Y, Nakayama N, Kosaka K, Shimojo Y, Kitajima C, Itoh K, Yokoi T, Shirasawa T.
Neurosci Lett. 2008 Apr 4;434(3):260-5. doi: 10.1016/j.neulet.2008.01.079. Epub 2008 Feb 13.
PMID 18329808
Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells.
Schultz MA, Hagan SS, Datta A, Zhang Y, Freeman ML, Sikka SC, Abdel-Mageed AB, Mondal D.
PLoS One. 2014 Jan 22;9(1):e87204. doi: 10.1371/journal.pone.0087204. eCollection 2014.
PMID 24466341
The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?
Shelton P, Jaiswal AK.
FASEB J. 2013 Feb;27(2):414-23. doi: 10.1096/fj.12-217257. Epub 2012 Oct 29. (REVIEW)
PMID 23109674
Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice.
Shen G, Xu C, Hu R, Jain MR, Nair S, Lin W, Yang CS, Chan JY, Kong AN.
Pharm Res. 2005 Nov;22(11):1805-20. Epub 2005 Aug 16.
PMID 16132347
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M.
Neoplasia. 2011 Sep;13(9):864-73.
PMID 21969819
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S.
Proc Natl Acad Sci U S A. 2008b Sep 9;105(36):13568-73. doi: 10.1073/pnas.0806268105. Epub 2008 Aug 29.
PMID 18757741
Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S.
Cancer Res. 2010 Nov 15;70(22):9095-105. doi: 10.1158/0008-5472.CAN-10-0384. Epub 2010 Nov 9.
PMID 21062981
Polymorphism of Nrf2, an antioxidative gene, is associated with blood pressure and cardiovascular mortality in hemodialysis patients.
Shimoyama Y, Mitsuda Y, Tsuruta Y, Hamajima N, Niwa T.
Int J Med Sci. 2014 May 10;11(7):726-31. doi: 10.7150/ijms.8590. eCollection 2014.
PMID 24904228
NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis.
Shin S, Wakabayashi N, Misra V, Biswal S, Lee GH, Agoston ES, Yamamoto M, Kensler TW.
Mol Cell Biol. 2007 Oct;27(20):7188-97. Epub 2007 Aug 20.
PMID 17709388
Role of the Nrf2-ARE pathway in liver diseases.
Shin SM, Yang JH, Ki SH.
Oxid Med Cell Longev. 2013;2013:763257. doi: 10.1155/2013/763257. Epub 2013 May 9. (REVIEW)
PMID 23766860
Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population.
Siedlinski M, Postma DS, Boer JM, van der Steege G, Schouten JP, Smit HA, Boezen HM.
Respir Res. 2009 Aug 11;10:73. doi: 10.1186/1465-9921-10-73.
PMID 19671143
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II.
Clin Cancer Res. 2010 Jul 15;16(14):3743-53. doi: 10.1158/1078-0432.CCR-09-3352. Epub 2010 Jun 9.
PMID 20534738
NRF2 and cancer: the good, the bad and the importance of context.
Sporn MB, Liby KT.
Nat Rev Cancer. 2012 Jul 19;12(8):564-71. doi: 10.1038/nrc3278.
PMID 22810811
Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis.
Stepkowski TM, Kruszewski MK.
Free Radic Biol Med. 2011 May 1;50(9):1186-95. doi: 10.1016/j.freeradbiomed.2011.01.033. Epub 2011 Feb 2.
PMID 21295136
Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response.
Sun Z, Chin YE, Zhang DD.
Mol Cell Biol. 2009 May;29(10):2658-72. doi: 10.1128/MCB.01639-08. Epub 2009 Mar 9.
PMID 19273602
Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice.
Sussan TE, Jun J, Thimmulappa R, Bedja D, Antero M, Gabrielson KL, Polotsky VY, Biswal S.
PLoS One. 2008;3(11):e3791. doi: 10.1371/journal.pone.0003791. Epub 2008 Nov 21.
PMID 19023427
Stress-activated cap'n'collar transcription factors in aging and human disease.
Sykiotis GP, Bohmann D.
Sci Signal. 2010 Mar 9;3(112):re3. doi: 10.1126/scisignal.3112re3. (REVIEW)
PMID 20215646
Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism.
Tong KI, Kobayashi A, Katsuoka F, Yamamoto M.
Biol Chem. 2006 Oct-Nov;387(10-11):1311-20. (REVIEW)
PMID 17081101
The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease.
Tufekci KU, Civi Bayin E, Genc S, Genc K.
Parkinsons Dis. 2011 Feb 22;2011:314082. doi: 10.4061/2011/314082.
PMID 21403858
Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.
Villeneuve NF, Lau A, Zhang DD.
Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712. doi: 10.1089/ars.2010.3211. Epub 2010 Aug 14. (REVIEW)
PMID 20486766
When NRF2 talks, who's listening?
Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW.
Antioxid Redox Signal. 2010 Dec 1;13(11):1649-63. doi: 10.1089/ars.2010.3216. Epub 2010 Jul 9. (REVIEW)
PMID 20367496
RXRa inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2.
Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li Y, Luo L, Hayes JD, Wang XJ, Tang X.
Cancer Res. 2013 May 15;73(10):3097-108. doi: 10.1158/0008-5472.CAN-12-3386. Epub 2013 Apr 23.
PMID 23612120
Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival.
Wang J, Zhang M, Zhang L, Cai H, Zhou S, Zhang J, Wang Y.
J Surg Res. 2010 Nov;164(1):e99-105. doi: 10.1016/j.jss.2010.05.058. Epub 2010 Jun 16.
PMID 20828733
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues.
Wang R, An J, Ji F, Jiao H, Sun H, Zhou D.
Biochem Biophys Res Commun. 2008 Aug 15;373(1):151-4. doi: 10.1016/j.bbrc.2008.06.004. Epub 2008 Jun 12.
PMID 18555005
Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice.
Wruck CJ, Fragoulis A, Gurzynski A, Brandenburg LO, Kan YW, Chan K, Hassenpflug J, Freitag-Wolf S, Varoga D, Lippross S, Pufe T.
Ann Rheum Dis. 2011 May;70(5):844-50. doi: 10.1136/ard.2010.132720. Epub 2010 Dec 20.
PMID 21173018
Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T, Ishii Y, Homma S, Morishima Y, Kurishima K, Itoh K, Yamamoto M, Minami Y, Noguchi M, Hizawa N.
Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16.
PMID 22249257
Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity.
Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, Yamamoto M.
Mol Cell Biol. 2008 Apr;28(8):2758-70. doi: 10.1128/MCB.01704-07. Epub 2008 Feb 11.
PMID 18268004
Somatic mutations of the KEAP1 gene in common solid cancers.
Yoo NJ, Kim HR, Kim YR, An CH, Lee SH.
Histopathology. 2012 May;60(6):943-52. doi: 10.1111/j.1365-2559.2012.04178.x. Epub 2012 Feb 20.
PMID 22348534
Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.
Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN.
PLoS One. 2010 Jan 5;5(1):e8579. doi: 10.1371/journal.pone.0008579.
PMID 20062804
Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.
Zhang C, Su ZY, Khor TO, Shu L, Kong AN.
Biochem Pharmacol. 2013 May 1;85(9):1398-404. doi: 10.1016/j.bcp.2013.02.010. Epub 2013 Feb 14.
PMID 23416117
Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress.
Zhang DD, Hannink M.
Mol Cell Biol. 2003 Nov;23(22):8137-51.
PMID 14585973
Mechanistic studies of the Nrf2-Keap1 signaling pathway.
Zhang DD.
Drug Metab Rev. 2006;38(4):769-89. (REVIEW)
PMID 17145701
Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG, Manolakou SD, Habeos IG, Lilis I, Chartoumpekis DV, Koika V, Soares P, Kyriazopoulou VE, Scopa CD, Papachristou DJ, Sykiotis GP.
J Clin Endocrinol Metab. 2013 Aug;98(8):E1422-7. doi: 10.1210/jc.2013-1510. Epub 2013 Jun 13.
PMID 23766517
Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?
de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, van Horssen J.
Free Radic Biol Med. 2008 Nov 15;45(10):1375-83. doi: 10.1016/j.freeradbiomed.2008.09.001. Epub 2008 Sep 13. (REVIEW)
PMID 18824091


This paper should be referenced as such :
Stavroula D Manolakou, Panos G Ziros, Gerasimos P Sykiotis
NFE2L2 (nuclear factor, erythroid 2-like 2)
Atlas Genet Cytogenet Oncol Haematol. 2015;19(8):503-521.
Free journal version : [ pdf ]   [ DOI ]

External links

HGNC (Hugo)NFE2L2   7782
Entrez_Gene (NCBI)NFE2L2    nuclear factor, erythroid 2 like 2
AliasesHEBP1; IMDDHH; NRF2; Nrf-2
GeneCards (Weizmann)NFE2L2
Ensembl hg19 (Hinxton)ENSG00000116044 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000116044 [Gene_View]  ENSG00000116044 [Sequence]  chr2:177230309-177264727 [Contig_View]  NFE2L2 [Vega]
ICGC DataPortalENSG00000116044
TCGA cBioPortalNFE2L2
AceView (NCBI)NFE2L2
Genatlas (Paris)NFE2L2
SOURCE (Princeton)NFE2L2
Genetics Home Reference (NIH)NFE2L2
Genomic and cartography
GoldenPath hg38 (UCSC)NFE2L2  -     chr2:177230309-177264727 -  2q31.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)NFE2L2  -     2q31.2   [Description]    (hg19-Feb_2009)
GoldenPathNFE2L2 - 2q31.2 [CytoView hg19]  NFE2L2 - 2q31.2 [CytoView hg38]
genome Data Viewer NCBINFE2L2 [Mapview hg19]  
OMIM600492   617744   
Gene and transcription
Genbank (Entrez)AB208786 AF323119 AK297838 AK304555 AK310656
RefSeq transcript (Entrez)NM_001145412 NM_001145413 NM_001313900 NM_001313901 NM_001313902 NM_001313903 NM_001313904 NM_006164
Consensus coding sequences : CCDS (NCBI)NFE2L2
Alternative Splicing GalleryENSG00000116044
Gene ExpressionNFE2L2 [ NCBI-GEO ]   NFE2L2 [ EBI - ARRAY_EXPRESS ]   NFE2L2 [ SEEK ]   NFE2L2 [ MEM ]
Gene Expression Viewer (FireBrowse)NFE2L2 [ Firebrowse - Broad ]
GenevisibleExpression of NFE2L2 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4780
GTEX Portal (Tissue expression)NFE2L2
Human Protein AtlasENSG00000116044-NFE2L2 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ16236   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ16236  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ16236
Domaine pattern : Prosite (Expaxy)BZIP (PS50217)    BZIP_BASIC (PS00036)   
Domains : Interpro (EBI)bZIP    bZIP_Maf    Nrf2    TF_DNA-bd_sf   
Domain families : Pfam (Sanger)bZIP_Maf (PF03131)   
Domain families : Pfam (NCBI)pfam03131   
Domain families : Smart (EMBL)BRLZ (SM00338)  
Conserved Domain (NCBI)NFE2L2
PDB (RSDB)2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
PDB Europe2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
PDB (PDBSum)2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
PDB (IMB)2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
Structural Biology KnowledgeBase2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
SCOP (Structural Classification of Proteins)2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
CATH (Classification of proteins structures)2FLU    2LZ1    3ZGC    4IFL    5WFV    6T7V   
AlphaFold pdb e-kbQ16236   
Human Protein Atlas [tissue]ENSG00000116044-NFE2L2 [tissue]
Protein Interaction databases
IntAct (EBI)Q16236
Ontologies - Pathways
Ontology : AmiGOchromatin  transcription cis-regulatory region binding  transcription cis-regulatory region binding  RNA polymerase II cis-regulatory region sequence-specific DNA binding  DNA-binding transcription factor activity, RNA polymerase II-specific  DNA-binding transcription factor activity, RNA polymerase II-specific  transcription coregulator binding  DNA-binding transcription activator activity, RNA polymerase II-specific  DNA binding  DNA-binding transcription factor activity  protein binding  nucleus  nucleus  nucleoplasm  cytoplasm  Golgi apparatus  centrosome  cytosol  plasma membrane  regulation of transcription by RNA polymerase II  inflammatory response  aging  response to lithium ion  proteasomal ubiquitin-independent protein catabolic process  positive regulation of gene expression  positive regulation of gene expression  negative regulation of cardiac muscle cell apoptotic process  positive regulation of neuron projection development  protein ubiquitination  protein domain specific binding  positive regulation of blood coagulation  endoplasmic reticulum unfolded protein response  protein-DNA complex  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to drug  positive regulation of transcription from RNA polymerase II promoter in response to stress  positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress  PERK-mediated unfolded protein response  PERK-mediated unfolded protein response  cellular response to glucose starvation  proteasome-mediated ubiquitin-dependent protein catabolic process  positive regulation of blood vessel endothelial cell migration  sequence-specific DNA binding  cell redox homeostasis  positive regulation of angiogenesis  positive regulation of transcription by RNA polymerase II  positive regulation of transcription by RNA polymerase II  positive regulation of transcription by RNA polymerase II  regulation of embryonic development  aflatoxin catabolic process  positive regulation of glucose import  positive regulation of transcription from RNA polymerase II promoter in response to hypoxia  RNA polymerase II-specific DNA-binding transcription factor binding  cellular response to hydrogen peroxide  cellular response to copper ion  cellular response to tumor necrosis factor  cellular response to fluid shear stress  cellular response to laminar fluid shear stress  negative regulation of hematopoietic stem cell differentiation  negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway  positive regulation of ER-associated ubiquitin-dependent protein catabolic process  negative regulation of hydrogen peroxide-induced cell death  positive regulation of glutathione biosynthetic process  cellular response to angiotensin  negative regulation of vascular associated smooth muscle cell migration  regulation of removal of superoxide radicals  negative regulation of endothelial cell apoptotic process  positive regulation of reactive oxygen species metabolic process  
Ontology : EGO-EBIchromatin  transcription cis-regulatory region binding  transcription cis-regulatory region binding  RNA polymerase II cis-regulatory region sequence-specific DNA binding  DNA-binding transcription factor activity, RNA polymerase II-specific  DNA-binding transcription factor activity, RNA polymerase II-specific  transcription coregulator binding  DNA-binding transcription activator activity, RNA polymerase II-specific  DNA binding  DNA-binding transcription factor activity  protein binding  nucleus  nucleus  nucleoplasm  cytoplasm  Golgi apparatus  centrosome  cytosol  plasma membrane  regulation of transcription by RNA polymerase II  inflammatory response  aging  response to lithium ion  proteasomal ubiquitin-independent protein catabolic process  positive regulation of gene expression  positive regulation of gene expression  negative regulation of cardiac muscle cell apoptotic process  positive regulation of neuron projection development  protein ubiquitination  protein domain specific binding  positive regulation of blood coagulation  endoplasmic reticulum unfolded protein response  protein-DNA complex  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to oxidative stress  cellular response to drug  positive regulation of transcription from RNA polymerase II promoter in response to stress  positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress  PERK-mediated unfolded protein response  PERK-mediated unfolded protein response  cellular response to glucose starvation  proteasome-mediated ubiquitin-dependent protein catabolic process  positive regulation of blood vessel endothelial cell migration  sequence-specific DNA binding  cell redox homeostasis  positive regulation of angiogenesis  positive regulation of transcription by RNA polymerase II  positive regulation of transcription by RNA polymerase II  positive regulation of transcription by RNA polymerase II  regulation of embryonic development  aflatoxin catabolic process  positive regulation of glucose import  positive regulation of transcription from RNA polymerase II promoter in response to hypoxia  RNA polymerase II-specific DNA-binding transcription factor binding  cellular response to hydrogen peroxide  cellular response to copper ion  cellular response to tumor necrosis factor  cellular response to fluid shear stress  cellular response to laminar fluid shear stress  negative regulation of hematopoietic stem cell differentiation  negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway  positive regulation of ER-associated ubiquitin-dependent protein catabolic process  negative regulation of hydrogen peroxide-induced cell death  positive regulation of glutathione biosynthetic process  cellular response to angiotensin  negative regulation of vascular associated smooth muscle cell migration  regulation of removal of superoxide radicals  negative regulation of endothelial cell apoptotic process  positive regulation of reactive oxygen species metabolic process  
Pathways : BIOCARTAOxidative Stress Induced Gene Expression Via Nrf2 [Genes]    Prion Pathway [Genes]   
Pathways : KEGGProtein processing in endoplasmic reticulum   
NDEx NetworkNFE2L2
Atlas of Cancer Signalling NetworkNFE2L2
Wikipedia pathwaysNFE2L2
Orthology - Evolution
GeneTree (enSembl)ENSG00000116044
Phylogenetic Trees/Animal Genes : TreeFamNFE2L2
Homologs : HomoloGeneNFE2L2
Homology/Alignments : Family Browser (UCSC)NFE2L2
Gene fusions - Rearrangements
Fusion : MitelmanNFE2L2/PDE11A [2q31.2/2q31.2]  
Fusion : MitelmanNFE2L2/RFTN2 [2q31.2/2q33.1]  
Fusion : MitelmanNFE2L2/ZC3H13 [2q31.2/13q14.13]  
Fusion : MitelmanPAX8/NFE2L2 [2q13/2q31.2]  
Fusion PortalNFE2L2 2q31.2 PDE11A 2q31.2 LUSC
Fusion PortalNFE2L2 2q31.2 RFTN2 2q33.1 HNSC
Fusion PortalNFE2L2 2q31.2 ZC3H13 13q14.13 LUSC
Fusion PortalPAX8 2q13 NFE2L2 2q31.2 THCA
Fusion : QuiverNFE2L2
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerNFE2L2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)NFE2L2
Exome Variant ServerNFE2L2
GNOMAD BrowserENSG00000116044
Varsome BrowserNFE2L2
Genomic Variants (DGV)NFE2L2 [DGVbeta]
DECIPHERNFE2L2 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisNFE2L2 
ICGC Data PortalNFE2L2 
TCGA Data PortalNFE2L2 
Broad Tumor PortalNFE2L2
OASIS PortalNFE2L2 [ Somatic mutations - Copy number]
Cancer Gene: CensusNFE2L2 
Somatic Mutations in Cancer : COSMICNFE2L2  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DNFE2L2
Mutations and Diseases : HGMDNFE2L2
intOGen PortalNFE2L2
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
BioMutasearch NFE2L2
DgiDB (Drug Gene Interaction Database)NFE2L2
DoCM (Curated mutations)NFE2L2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)NFE2L2 (select a term)
NCG6 (London) select NFE2L2
Cancer3DNFE2L2(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
OMIM600492    617744   
Genetic Testing Registry NFE2L2
NextProtQ16236 [Medical]
Target ValidationNFE2L2
Huge Navigator NFE2L2 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDNFE2L2
Pharm GKB GenePA31588
Clinical trialNFE2L2
DataMed IndexNFE2L2
PubMed499 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Sep 15 23:51:01 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us